Drugs / Gamitrinib
Gamitrinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04827810 | Nov 2021 → Jun 2026 overdue | lymphoma | Fox Chase Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gamitrinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04827810 ↗ |
| Known as | G-tpp | ChEMBL registry synonym — accepted as the source's own label CHEMBL4646511 ↗ |
| Known as | Gamitrinib tpp | ChEMBL registry synonym — accepted as the source's own label CHEMBL4646511 ↗ |
| Action | Inhibit | “small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib” NCT04827810 ↗ |
| Modality | Small molecule | “small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib” NCT04827810 ↗ |
| Route | Intravenous | “gamitrinib formulated in Lipoid S100®-based formulation will be administered as a 1-hour IV infusion once weekly for four weeks” NCT04827810 ↗ |